Scientists have developed broad-spectrum inhibitors of the influenza virus using artificial peptide molecules...
List view / Grid view
Janssen Research & Development
Filter the results
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
12 June 2014 | By GlaxoSmithKline
ViiV Healthcare announced that they have entered into an agreement with Janssen R&D Ireland Ltd for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®1)...
Independent Data Monitoring Committee recommends early stopping of Phase 3 study of Ibrutinib in relapsed/refractory CLL/SLL patients
8 January 2014 | By Johnson & Johnson
Janssen announced the early stopping of PCYC-1112-CA based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival...